Links to other pages within Patient UK which are related to this topic:
Experience | Leaflets | Support | Patient+ | Guidelines | Weblinks | Videos | News | Products | Other
Print options:   Other options:   Bookmark and Share

This is a PatientPlus article. PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Heart Failure Management

Post your experience
See others (7 there)

See related article Heart Failure Diagnosis and Investigation.

Aims1

  1. Reducing morbidity, improving symptom-control and quality of life via:
    • Drugs - diuretics, inotropes, ACE inhibitors/angiotensin receptor blockade, digoxin
    • Non-drug interventions - e.g. revascularisation, valvular surgery, resynchronisation therapy, cardiac rehabilitation
    • Facilitating patient self-care
    • Psychological and social support
    • Palliative care
  2. Reducing mortality and prolonging survival through evidence-based use of:
    • Drugs:
      • ACE inhibitors/angiotensin receptor blockade
      • Beta blockers
      • Aldosterone antagonists
      • Nitrates
    • Non-drug therapies - e.g. implantable cardiac defibrillator, cardiac transplantation
  3. Prevention of:
    • Progression of myocardial damage
    • Hospitalisation

Chronic heart failure may be 'compensated' and stable with few signs and baseline symptoms, or 'decompensated' with a recent clinical deterioration and physical evidence of impaired perfusion and oxygenation. In cases of decompensation, always consider both the original aetiology of the heart failure and potential causes of any deterioration, such as:

  • Further/worsening ischaemia
  • Myocardial infarction
  • Additional valvular or diastolic dysfunction
  • Infections
  • Arrhythmias (commonly AF)
  • Electrolyte imbalance
  • Worsening co-morbidities - e.g. anaemia, thyroid dysfunction, pulmonary disease, renal dysfunction, diabetes
  • New medications
General measures1

Patient education and self-care

Patient and family education and training in self-care is effective at improving adherence, symptom control, functional capacity and well-being. Topics should include:

  • Nature and cause of symptoms
  • Available treatments, likely side-effects and responses
  • Recognition and reaction to symptoms (e.g. flexible dosing of diuretics which can be titrated to symptoms with advice as to when to contact the healthcare team)
  • Risk factor modification
  • Dietary and exercise advice
  • Psychosocial aspects to the disease
  • Prognosis

Specialist heart failure nurses2

Community-based heart failure nurses provide an important adjunct to self-care, as well as a bridge to secondary care. Referral of those with moderate to severe heart failure to such a service improves symptom management, reduces hospital admissions and also assists in the transition to a palliative care approach when appropriate.

Lifestyle modification

Smoking

Encourage to stop smoking and provide support with smoking cessation.

Diet and fluid intake

  • Advise regarding good nutrition and provide help for obese patients to reduce their weight. Cachexic patients (weight loss over 6 months >6% of previous, stable body weight) should be assessed by a dietician.
  • Suggest patients avoid foods with a high-salt content and do not add salt to their food. Salt intake should not exceed 2-3 g per day. Consider moderate sodium restriction in severe CCF; take care that 'low-salt' alternatives are not over-used as they can be very rich in potassium which may be a problem for patients on ACE inhibitors or spironolactone.
  • Advise patients with severe CCF, particularly in conjunction with hyponatraemia, to restrict their fluid intake sensibly. Take care to avoid excessive dehydration – particularly in elderly patients on high-dose diuretics.
  • Patients can contribute to monitoring their fluid retention by regularly weighing themselves. Where a sudden, unexpected weight gain of >2 kg in 3 days, advice should be sought. Some patients may benefit from being able to vary their diuretic dose on the basis of regular weights. Self-weighing complements ongoing monitoring of weight in the GP surgery, hospital outpatient and inpatient wards.

Alcohol

Alcohol can act as a negative inotrope, increase blood pressure and the risk of arrhythmias. Restrict alcohol intake to 10-20 g/day (equivalent to 1-2 glasses of wine) or advise abstention if alcohol-induced cardiomyopathy.

Exercise

Encourage aerobic exercise, preferably as part of a supervised cardiac rehabilitation programme, for patients with heart failure up to and including NYHA grade III which has proven beneficial effect.3

Travel

Air travel is not restricted in stable patients (and may be preferable to other means of transportation for long journeys); however, long-haul flights increase the risk of peripheral oedema and DVT. High altitudes and travel to very hot and humid areas should be discouraged in symptomatic patients who may not adapt easily.

Sex and reproductive health

  • There are no specific restrictions for sexual activity, although there is a slight risk of decompensation in those with NHYA class III-IV.
  • Advise patients that symptoms such as dyspnoea, palpitations, angina are unlikely to occur related to sex unless similar symptoms are experienced with moderate exercise (e.g. climbing two flights of stairs reasonably quickly). Sexual activity is least likely to cause symptoms if engaged in following sleep, with the least affected partner doing most of the physical work. The most provocative occasions will be sex with a new partner, after a hot bath or on a full stomach.
  • Sexual problems are common in patients with heart failure related to concurrent cardiovascular disease, side-effects of treatment (e.g. beta blockers) and psychological factors.
    • Sublingual glycerol trinitrate may be used prophylactically against dyspnoea and chest pain during sex but nitrates must never be combined with phosphodiesterase inhibitors such as sildenafil.
    • Phosphodiesterase inhibitors are not currently recommended for use in those with advanced heart failure.
  • Pregnancy risks worsening of heart failure due to increased blood volume and cardiac output and many relevant medications are contra-indicated in pregnancy. Potentially fertile women with heart failure should receive prenatal counselling to enable informed reproductive choice.

Mental health and well-being

Depression is very common in heart failure, occurring in at least 1 in 5 patients and at much higher levels in those with advanced disease. Screening and appropriate treatment should be considered in those with symptoms.

Immunisation

Offer:

Drug therapy4

See Acute Pulmonary Oedema Management article.

Summary of drug interventions:4

Asymptomatic left ventricular systolic dysfunction

  1. ACE inhibitor
  2. Consider beta blockers

Symptomatic left ventricular systolic dysfunction

  1. ACE inhibitor
  2. Diuretics if evidence of fluid retention
  3. Beta blockers once stabilised (even if no longer symptomatic)

Severe or refractory heart failure (usually following specialist referral)

  1. Consider the addition of:
  2. Third line drugs include:
  3. Non-drug options may be indicated:


Note that a significant proportion of patients with chronic heart failure are symptomatic but have preserved left ventricle systolic function. This has been variously classified as diastolic heart failure, heart failure with preserved LV function or heart failure with a normal ejection fraction (HFNEF)5 Elderly women with co-morbidities such as hypertension, ischaemic heart disease and diabetes are over-represented in this group. The evidence base for their treatment is much more limited:4,6

  • Treat the co-morbidities aggressively.
  • Best evidence is for the use of angiotensin receptor agonists (more limited for ACEI).
  • Use diuretics if pulmonary or systemic congestion but avoid over-diuresis.
  • Consider the use of beta blockers.
  • Refer to cardiologist for full assessment and review of treatment.

ACE Inhibitors1

  • All patients with a left ventricular ejection fraction (LVEF) of 40% or less, regardless of symptom severity, should receive an ACE inhibitor unless contraindicated or not tolerated.7
  • This is because ACE inhibitors have been shown to improve ventricular function and patient well-being, to reduce mortality and hospital admissions in many large clinical trials and are indicated in all stages of left ventricular systolic dysfunction (LVSD).
  • Contra-indications include a history of angioedema, bilateral renal artery stenosis, hyperkalaemia (>5 mmol/l), severe renal impairment (serum creatinine >220 μmol/l) and severe aortic stenosis.
  • Check U&Es and renal function prior to starting treatment and then after 1-2 weeks of treatment or dose adjustment.
  • Titrate dose up after 2-4 weeks, provided there is no worsening of renal function or hyperkalaemia, aiming for the evidence-based target dose or maximum tolerated dose.
  • Recheck U&Es at 1, 3 and 6 months after achieving maintenance dose and twice-yearly thereafter.
  • If renal function worsens, check and eliminate other nephrotoxic drugs such as NSAIDs. An increase of up to 50% from baseline or to an absolute creatinine concentration of 265 μmol/l is deemed acceptable, but above this reduce the ACEI dose. Stop the ACEI where the creatinine concentration is ≥310 μmol/l.
  • Warn patient regarding initial symptoms of dizziness, where this does not improve with time or causes risk of falling, reduce dose or stop other hypotensive medications. Switch to an angiotensin receptor blocker if chronic cough develops.

Diuretics1

  • Symptomatic failure usually requires loop diuretics such as furosemide (formerly frusemide). Diuretics give symptom relief but do not alter prognosis. They should usually be used in combination with an ACE inhibitor.
  • Give initial doses intravenously in cases of severe failure as their onset of action is faster (5 minutes compared to 1–2 hours p.o.) and oral absorption may be reduced by intestinal mucosal oedema (bumetanide has slightly better bioavailability in the oedematous gut).
  • Beware of both over- and under-treatment with diuretics (start with low dose and increase depending on response), and review clinical condition and electrolytes regularly – watch for hypokalaemia, hypovolaemia leading to circulatory collapse and uraemia, particularly in the older patient. Note that creatinine is not a reliable indicator of overall renal function and that GFR may be reduced by up to 75% before it begins to rise, particularly in patients with a low muscle mass.
  • Weight monitoring is invaluable in assessing the degree of fluid retention and optimal diuretic strategy. Aim to maintain 'dry weight' with the lowest achievable dose of diuretic.
  • Where diuretic response is insufficient:
    • Check compliance and fluid intake.
    • Increase dose of diuretic.
    • Consider switch from furosemide to bumetanide or torasemide.
    • Add an aldosterone antagonist.
    • Combine a loop diuretic with a thiazide (e.g. metolazone)
    • Give the loop diuretic b.d. or on an empty stomach.
    • Consider short-term use of IV infusion of loop diuretic.
  • Excessive diuresis increases the risk of hypotension and renal dysfunction associated with ACE inhibitor therapy. Where ACE inhibitors or aldosterone antagonists are used with a diuretic, potassium replacement is not usually required.

Beta blockers1,8

  • Current guidance suggests that beta blockers should be used in all patients with symptomatic heart failure and an LVEF ≤40%, where tolerated and not contra-indicated. Trial evidence shows beta blockers increase ejection fraction, exercise tolerance, reduce morbidity, mortality and hospital admissions additional to that produced by co-prescription of ACE inhibitors.
  • They should be initiated in stabilised patients already on diuretics and ACE inhibitors, regardless of whether or not symptoms persist (NICE guidance).7
  • Evidence for the benefit of beta blockade in heart failure is limited to bisoprolol, carvedilol, metoprolol and nebivolol. We cannot assume that it is a class effect despite NICE guidance that if patients were already taking a non-recommended beta blocker such as atenolol, they should continue with this. Updated QOF targets for 2009/10 will look at the percentage of patients with heart failure on beta blockers licensed for that indication, i.e. bisoprolol, carvedilol and nebrivolol.
  • A study looking at beta blocker prescribing in British General Practice between 2000-2005 showed that only about a fifth of patients with heart failure received beta blockers.9 A major barrier to this practice is the prior, longstanding contra-indication of beta blockers in heart failure and concerns about the difficulty of initiating beta blockers in such patients.10 This was based on the belief that sudden loss of sympathetic drive to the failing myocardium would precipitate worse failure. This has been demonstrated not to be the case and low-dose treatment with cardio-selective beta blockers can be safely initiated/titrated in the community in elderly patients and others with relative contra-indications (e.g. diabetes, mild hypotension, fixed airways obstruction).
  • Asthma, second- or third-degree heart block, sick sinus syndrome (without pacemaker) and sinus bradycardia (<50 beats per minute) remain contra-indications to beta blocker use.
  • Initiate at low dose, with increases every 2-3 weeks until the target evidence-based dose or maximum tolerated dose are reached.
  • Monitor blood pressure and heart rate with each increase in dose. If hypotensive, discontinue other vasodilator drugs (e.g. nitrates, calcium channel blockers) where possible. Where bradycardia (<60 beats per min) develops, stop other contributory medications (e.g. digoxin, amiodarone).
  • Do not abruptly stop beta blockers as this risks an MI or arrhythmia.

Angiotensin II receptor antagonists1

  • Angiotensin II receptor antagonists can be used in patients intolerant of standard ACE inhibitors. Candesartan and valsartan are now licensed for this indication. They do not cause the chronic cough side-effect associated with ACE inhibitors.
  • They are also recommended in combination with an ACEI and a beta blocker in patients with heart failure and an LVEF ≤40% who nonetheless remain symptomatic.
  • They must only be used in patients with adequate renal function and a normal serum potassium. Serial monitoring of renal function and U&Es is vital, particularly when used in combination with an ACE inhibitor.

Aldosterone antagonists1

  • A low-dose aldosterone antagonist should be considered in all patients with an LVEF ≤35% and severe symptoms (NHYA class III or IV), unless contra-indicated or not tolerated and in the absence of hyperkalaemia and significant renal dysfunction.
  • The RALES study suggested that, in moderate or severe heart failure, the combination of ACE inhibitor, loop diuretic and spironolactone reduces deterioration and mortality.11
  • Hyperkalaemia was unlikely under trial conditions where low doses of spironolactone were used (<25 mg/day)12 but is more common in clinical practice, particularly in elderly patients or those with poor renal function. The combination of an ACE inhibitor and aldosterone antagonist increases the risk of severe hyperkalaemia and careful monitoring is required.
  • Measure renal function and U&Es at 1 week and 4 weeks after starting/increasing dose. This should be repeated monthly for the first 3 months and then at least twice a year on maintenance treatment.
  • Where breast tenderness or enlargement occurs, switch from spironlactone to eplerenone.

Digoxin1

  • In atrial fibrillation, digoxin is very useful in controlling heart rate, and as a positive inotrope where there is concomitant heart failure. It is often used to gain initial rate control and to treat decompensated heart failure prior to the initiation of a beta blocker. In the longer term, a beta blocker, either alone or in combination with digoxin, is preferred for rate control in patients with an LVEF ≤40%.
  • It also improves symptoms in those patients with moderate and severe failure who are in sinus rhythm, and hence should be considered if symptoms of failure continue in spite of optimal treatment with diuretics and ACE inhibitors.
  • Digoxin is of use in severe LVSD and, whilst it does not appear to alter mortality rates, did appear to help prevent recurrent admissions to hospital.13,14
  • A single daily maintenance dose of 0.25 mg is suggested in adults with normal renal function (reduced to 0.125 or 0.0625 mg in the elderly or those with renal impairment).
  • In patients on digoxin, monitor U+E and maintain potassium at 4–5 mmol/l.
  • Digoxin levels may also need monitoring – 6 hrs post dose, to ensure therapeutic (but not toxic) levels. Therapeutic range occurs between 0.6-1.2 ng/ml.
  • For use of other inotropes (e.g. dobutamine) click here to see article on Acute Pulmonary Oedema Management.

Vasodilators1

  • Long-acting nitrates work in a complex manner by reducing venous filling pressure (preload), reducing output impedance and improving coronary filling.
  • They are particularly appropriate if the patient has episodes of angina.
  • H-ISDN does reduce mortality (although inferior to ACE inhibitors) in symptomatic patients with LVEF ≤40% and such a combination may be considered in patients intolerant of ACE inhibitors or those still symptomatic despite maximal first and second line therapy. Evidence is strongest in patients of an African-American descent.
  • Alpha-blockers should be avoided, as the ALLHAT hypertensive study suggests they cause significantly more congestive cardiac failure and cardiac events than a simple diuretic.15
  • Calcium channel blockers should also be avoided, as they are generally negatively inotropic and also increase morbidity and mortality. However, amlodipine is recommended by NICE to treat concomitant angina/hypertension as it appears to have no net effect.16

Opiates or opioids (morphine or diamorphine)

  • They may relieve anxiety, distress and pain and are important in the management of severe acute heart failure, or in terminal disease (particularly if difficulty sleeping).
  • They also produce transient venodilation, thus reducing cardiac filling pressures, preload and pulmonary congestion.

Drugs to treat cardiovascular co-morbidity1

Anticoagulants and antiplatelet agents

  • Patients with severe heart failure have a greater incidence of strokes and emboli.
  • Warfarin is recommended in patients with heart failure and permanent, persistent or paroxysmal AF without contra-indication to anticoagulation. It is also recommended for those with intracardiac thrombus or with evidence of systemic embolism.
  • Aspirin is less effective than warfarin in preventing thromboembolism in patients with AF. There is no evidence that antiplatelet agents reduce atherosclerotic risk in patients with heart failure but they are widely used in all patients with ischaemic heart disease without contraindications.
  • There has been a long-running controversy about a potential, negative interaction between aspirin and ACE inhibitors which now seems to have been largely discounted.

Statins

In elderly patients with symptomatic chronic heart failure caused by coronary artery disease, secondary prevention with statins may reduce hospitalisations.

Drugs to avoid in heart failure include:17

  • Pro-antiarrythmics with potentially negative inotropic effects, e.g. flecainide
  • Calcium blockers, e.g. verapamil, diltiazem (only amlodipine is advisable)
  • Tricyclic antidepressants
  • Lithium
  • NSAIDs and COX2 inhibitors18
  • Corticosteroids
  • Drugs prolonging QT interval and potentially precipitating ventricular arrhythmias, e.g. erythromycin, terfenadine

Non-drug therapies
  • Where heart failure is caused or exacerbated by surgically correctable conditions, these should be detected and treated appropriately by:
    • Revascularisation - surgical (coronary artery bypass grafting) or radiological (percutaneous coronary intervention) techniques should be considered in selected heart failure patients with coronary artery disease.
    • Valvular disease - decisions regarding surgery should be individualised. Medical management of heart failure and co-morbidities should be optimised prior to surgery.
  • Cardiomyoplasty and partial left ventriculectomy (Batista's operation) are not recommended as a treatment of heart failure or alternative to heart transplantation.19
  • Cardiac resynchronisation therapy (CRT), also known as biventricular pacing, is recommended to reduce mortality and morbidity in patients with moderate-to-severe heart failure who remain symptomatic despite optimal medical therapy, have a reduced LVEF ≤35% and QRS prolongation (≥120 ms).20 Pacing improves the coordination of ventricular contraction with subsequent gains in cardiac output.
  • Implantable cardioverter defibrillator (ICD) is recommended:
    • For secondary prevention in survivors of ventricular fibrillation and for those who have experienced haemodynamically unstable VT or VT with syncope, in those with LVEF ≤40%, on optimal medical treatment and with an expectation of survival with good functional status of over a year.
    • For primary prevention in those with LV dysfunction due a previous MI or non-ischaemic cardiomyopathy, with an LVEF ≤35%, in NHYA functional class II or III, receiving optimal medical treatment and have a reasonable expectation of survival with good functional status of over a year.
  • CRS can be combined with ICD function but its survival benefit has yet to be determined.
  • Heart transplantation may be considered in selected patients when end-stage heart failure is reached without other treatment options. Constraints include lack of donor hearts and problems of rejection/long-term immunosuppression.
  • Left ventricular assist devices (LVADs) and artificial hearts are used currently for bridging to transplantation and managing patients with acute, severe myocarditis.

Indications for specialist referral include:

  • Diagnosis in doubt
  • Specialist investigations indicated
  • Murmurs and valve disease for further assessment
  • Co-existing arrhythmias, e.g. AF
  • Secondary causes, e.g. thyroid disease, suspected cardiomyopathy
  • Very poor ventricular function (ejection fraction <20%)
  • Metabolic abnormalities, e.g. hyponatraemia – Na <130 mmol/l, renal impairment
  • Renovascular disease
  • Relative hypotension (SBP <100 mmHg before ACE inhibitor therapy)
  • Poor response to initial lines of treatment - consideration for use of, for example, angiotensin receptor blockade or digoxin
  • Need for advice on managing deterioration in ischaemic heart disease symptoms
  • For consideration for non drug treatment, e.g. CRT, heart transplant

Palliative care6

See article Palliative Care of Heart Failure

There are considerable similarities between dying from cancer and dying from heart failure, with anxiety, severe dyspnoea and pain being prominent in both cases. Dissimilarities include the more uncertain trajectory compared to cancer - with periods of relative stability interspersed at increasing frequency by crises and the threat of sudden cardiac death.
The end-of-life care approach that evolved from the care of those with cancer is today being adapted for use with those with end-stage heart failure involving multi-disciplinary team working between palliative, cardiac and community health care teams. Generic palliative care needs exist and include the management of refractory symptoms, communication, advance planning and decision making issues, as well as the need for family support.

Prognosis

Prognosis is poor with around 80% of patients dying within 6 years of diagnosis. Optimal and early therapy with ACE inhibitors, beta blockers and appropriate non-pharmacological care can improve this outlook and it is hoped that the prognosis of the general heart failure population will improve as diagnoses are made earlier and optimal treatment strategies are followed.

The use of plasma BNP concentration monitoring to guide treatment may improve prognosis:21 patients with heart failure appear to do better where doctors try to achieve low level targets (<100 pg/ml) by applying more aggressive therapy,22 although no benefit over symptom-guided treatment has been found in other studies.23


Document references
  1. Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Society of Cardiology (January 2008); Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29(19):2388-442. Epub 2008 Sep 17.
  2. British Heart Foundation Factfile; Nurse-led, Home-based Management of Chronic Heart Failure. September 2002.
  3. Jonsdottir S, Andersen KK, Sigurosson AF, et al; The effect of physical training in chronic heart failure. Eur J Heart Fail. 2006 Jan;8(1):97-101. Epub 2005 Sep 27. [abstract]
  4. Heart failure, Map of Medicine (Cardiology)
  5. Sanderson JE; Heart failure with a normal ejection fraction. Heart. 2007 Feb;93(2):155-8. Epub 2005 Dec 30. [abstract]
  6. Heart failure - chronic, Clinical Knowledge Summaries (June 2009)
  7. Management of chronic heart failure in adults in primary and secondary care, NICE (July 2003)
  8. British Heart Foundation, Use of Beta blockers in heart failure (2006)
  9. Shah SM, Carey IM, DeWilde S, et al; Trends and inequities in beta-blocker prescribing for heart failure. Br J Gen Pract. 2008 Dec;58(557):862-9. [abstract]
  10. Krum H; Consider beta blockers for patients with heart failure. BMJ. 2009 Jun 1;338:b1728. doi: 10.1136/bmj.b1728.
  11. No authors listed; Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study ). Am J Cardiol. 1996 Oct 15;78(8):902-7. [abstract]
  12. Pitt B, Zannad F, Remme WJ, et al; The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.; N Engl J Med. 1999 Sep 2;341(10):709-17. [abstract]
  13. Young JB, Gheorghiade M, Uretsky BF, et al; Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. J Am Coll Cardiol. 1998 Sep;32(3):686-92. [abstract]
  14. Jaeschke R, Oxman AD, Guyatt GH; To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med. 1990 Mar;88(3):279-86. [abstract]
  15. Messerli FH; Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Lancet. 2000 Mar 11;355(9207):863-4.
  16. Packer M, O'Connor CM, Ghali JK, et al; Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996 Oct 10;335(15):1107-14. [abstract]
  17. Krum H, Abraham WT; Heart failure. Lancet. 2009 Mar 14;373(9667):941-55. [abstract]
  18. Gislason GH, Rasmussen JN, Abildstrom SZ, et al; Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009 Jan 26;169(2):141-9. [abstract]
  19. Partial left ventriculectomy, NICE (2004)
  20. Cubbon RM, Witte KK; Cardiac resynchronisation therapy for chronic heart failure and conduction delay. BMJ. 2009 Apr 28;338:b1265. doi: 10.1136/bmj.b1265.
  21. Richards AM, Troughton R, Lainchbury J, et al; Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies. J Card Fail. 2005 Jun;11(5 Suppl):S34-7. [abstract]
  22. British Heart Foundation, Role of BNP and Heart Failure (2008)
  23. Pfisterer M, Buser P, Rickli H, et al; BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009 Jan 28;301(4):383-92. [abstract]

Internet and further reading Acknowledgements EMIS is grateful to Dr Chloe Borton for writing this article and to Dr Sean Kavanagh for earlier versions. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2009.
Document ID: 236
Document Version: 23
Document Reference: bgp566
Last Updated: 22 Jul 2009
Planned Review: 22 Jul 2011

The authors and editors of this article are employed to create accurate and up to date content reflecting reliable research evidence, guidance and best clinical practice. They are free from any commercial conflicts of interest. Find out more about updating.

Patient UK Hearing Impairment Survey

Patient UK are grateful to the 550 people who took part in this survey.
To see the results click here.
If you'd like to leave your feedback, please go to our interactive forum.

Links to other pages within Patient UK which are related to this topic:
Experience | Leaflets | Support | Patient+ | Guidelines | Weblinks | Videos | News | Products | Other
Print options:   Other options:   Bookmark and Share
Want to search some more? Use the Google Search box below to search our site.

Related pages in Patient UK

Your Experience (^ top of page)

 Please add your experience about this condition / medicine
 View Patient Experience for 'Cardiac Failure' (7 there)
 Heart Failure

Support Group British Heart Foundation

 Acute Pulmonary Oedema
 Anti-arrhythmic Drugs
 Brain Natriuretic Peptide (BNP)
 Breathlessness
 Cardiovascular History and Examination
 Fluid Overload
 Heart Failure (Diagnosis and Investigation)
 Nurse-led, Home-based Management of Chronic Heart Failure
 Palliative Care of Heart Failure

 Guidelines on Heart Failure

 Heart Failure

 Links to online videos on Heart Failure

Recent related news items

 Link found between Alzheimer'sand heart disease
 Statins May Worsen Symptoms In Some Cardiac Patients
 Test 'spots blood disease danger'
 Diabetes drug taken by tens of thousands 'is linked to heart failure'
 A person's waist size is a predictor of heart health

All news by related topic

 Heart Failure news

Medical equipment

 Pill/Tablet Equipment

Visit the Patient UK Medical Equipment shop

Books

 Heart Failure (Understanding)
 Heart Failure : British Medical Association's Family Doctor Series

Visit the Patient UK shop

Other - Useful resources (^ top of page)

Pictures, diagrams, photos, images, etc.
Evidence based medicine
Online textbooks and journals
UK Guidelines
Online Videos
Medline
Other good health sites

Want to search some more? Use the Google Search box below to search our site.

Advertisements











Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>

Clicking here will take you to the foot of this page where you'll find a list of Information Leaflets which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Support Groups which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Medicines & Drugs which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of diagrams which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of PatientPlus (detailed reference) articles which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of UK Guidelines which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of other selected websites which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Poems and Stories which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Operations and Procedures which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Online Videos which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find links through to our interactive forum.
Here you can follow a link to view existing patient experiences on this subject, or to add your own
Clicking here will take you to the foot of this page where you'll find links to news stories on this subject in our Online Newspaper
Clicking here will take you to the foot of this page where you'll find links to related products
Clicking here will take you to the foot of this page where you'll find links to other useful sources of information
Click here to open a printer-friendly version of this document, in a new window, together with the print dialogue box
Click here to open this document in PDF format
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Click here to listen to the MP3 audio recording of this document
Click here to download the audio recording of this document as a podcast, for listening to at your leisure
Click here to open our Dictionaries and Glossaries page
Click here to see related products in our Online Pharmacy
Note: this will open in a new window
Click here to add this page to a social bookmarking site of your choice
Click here if you want to find out more about social bookmarking. This link will take you to the Wikipedia explanation
Note: this will open in a new window
Clicking here will take you to the foot of this page where you'll find a list of Information Leaflets which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Support Groups which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Medicines & Drugs which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of diagrams which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of PatientPlus (detailed reference) articles which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of UK Guidelines which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of other selected websites which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Poems and Stories which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Operations and Procedures which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Online Videos which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find links through to our interactive forum.
Here you can follow a link to view existing patient experiences on this subject, or to add your own
Clicking here will take you to the foot of this page where you'll find links to news stories on this subject in our Online Newspaper
Clicking here will take you to the foot of this page where you'll find links to related products
Clicking here will take you to the foot of this page where you'll find links to other useful sources of information
Click here to open a printer-friendly version of this document, in a new window, together with the print dialogue box
Click here to open this document in PDF format
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Click here to listen to the MP3 audio recording of this document
Click here to download the audio recording of this document as a podcast, for listening to at your leisure
Click here to open our Dictionaries and Glossaries page
Click here to see related products in our Online Pharmacy
Note: this will open in a new window
Click here to add this page to a social bookmarking site of your choice
Click here if you want to find out more about social bookmarking. This link will take you to the Wikipedia explanation
Note: this will open in a new window
Click here to return to the home page
Click here to read our 'About Us' page
Go to the Emis Access website, where you can book an appointment with your GP, order a repeat prescription or view you medical record online.
Note: this will open in a new window
View and/or join in discussion about health, lifestyle and disease in our interactive forum.
Note: this will open in a new window
Visit our pharmacy product price comparison website
Go to our online newspaper for current medical news and commentary.
Note: this will open in a new window
Adverts on this site do not influence the medical content. Click to read more.
Adverts on this site do not influence the medical content. Click to read more.